What's new

Assessment of public health risks related to antimicrobial resistance acquired via the environment, resulting from the use of a veterinary medicinal product - Scientific guideline

Assessment of public health risks related to antimicrob...

Apr 16, 2025 0

Assessment of public health risks related to antimicrobial resistance acquired v...

PSUSA/00002920/202408

PSUSA/00002920/202408

Apr 15, 2025 0

PSUSA/00002920/202408

Human medicines European public assessment report (EPAR): Zefylti, filgrastim, Date of authorisation: 12/02/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 15, 2025 0

Human medicines European public assessment report (EPAR): Zefylti, filgrastim, D...

Human medicines European public assessment report (EPAR): Tamiflu, oseltamivir, Date of authorisation: 20/06/2002, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 15, 2025 0

Human medicines European public assessment report (EPAR): Tamiflu, oseltamivir, ...

Human medicines European public assessment report (EPAR): Inovelon, rufinamide, Date of authorisation: 16/01/2007, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 15, 2025 0

Human medicines European public assessment report (EPAR): Inovelon, rufinamide, ...

Human medicines European public assessment report (EPAR): Flucelvax, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 15/11/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 15, 2025 0

Human medicines European public assessment report (EPAR): Flucelvax, influenza v...

Fees payable to the European Medicines Agency: Other fees and charges for medicinal products for human use, veterinary medicinal products and consultations on medical devices

Fees payable to the European Medicines Agency: Other fe...

Apr 15, 2025 0

Fees payable to the European Medicines Agency: Other fees and charges for medici...

Fees payable to the European Medicines Agency: Annual fees and remuneration

Fees payable to the European Medicines Agency: Annual f...

Apr 15, 2025 0

Fees payable to the European Medicines Agency: Annual fees and remuneration

Fees payable to the European Medicines Agency: Fees, charges and remuneration for assessment procedures and services relating to veterinary medicinal products

Fees payable to the European Medicines Agency: Fees, ch...

Apr 15, 2025 0

Fees payable to the European Medicines Agency: Fees, charges and remuneration fo...

Fees payable to the European Medicines Agency: Fees, charges and remuneration for assessment procedures and services relating to medicinal products for human use

Fees payable to the European Medicines Agency: Fees, ch...

Apr 15, 2025 0

Fees payable to the European Medicines Agency: Fees, charges and remuneration fo...

Fees payable to the European Medicines Agency

Fees payable to the European Medicines Agency

Apr 15, 2025 0

Fees payable to the European Medicines Agency

Human medicines European public assessment report (EPAR): Valdoxan, Agomelatine, Date of authorisation: 19/02/2009, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 15, 2025 0

Human medicines European public assessment report (EPAR): Valdoxan, Agomelatine,...

Fees payable to the European Medicines Agency: General questions and answers

Fees payable to the European Medicines Agency: General ...

Apr 15, 2025 0

Fees payable to the European Medicines Agency: General questions and answers

Pool of healthcare professional experts: list for 2024-...

Apr 15, 2025 0

Pool of healthcare professional experts: list for 2024-2029

Pool of patient and consumer experts: list for 2024-2029

Apr 15, 2025 0

Pool of patient and consumer experts: list for 2024-2029

Human medicines European public assessment report (EPAR): Mounjaro, tirzepatide, Date of authorisation: 15/09/2022, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 15, 2025 0

Human medicines European public assessment report (EPAR): Mounjaro, tirzepatide,...

Veterinary medicines European public assessment report (EPAR): Omeprazole TriviumVet, omeprazole, Status: Authorised

Veterinary medicines European public assessment report ...

Apr 15, 2025 0

Veterinary medicines European public assessment report (EPAR): Omeprazole Triviu...

Veterinary medicines European public assessment report (EPAR): Vectormune HVT-AIV, Avian influenza vaccine, Status: Authorised

Veterinary medicines European public assessment report ...

Apr 15, 2025 0

Veterinary medicines European public assessment report (EPAR): Vectormune HVT-AI...

Veterinary medicines European public assessment report (EPAR): Elmaro, maropitant, Status: Authorised

Veterinary medicines European public assessment report ...

Apr 15, 2025 0

Veterinary medicines European public assessment report (EPAR): Elmaro, maropitan...

Human medicines European public assessment report (EPAR): Prometax, rivastigmine, Date of authorisation: 04/12/1998, Revision: 50, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 15, 2025 0

Human medicines European public assessment report (EPAR): Prometax, rivastigmine...

Procedural advice on paediatric applications

Apr 15, 2025 0

Procedural advice on paediatric applications

Human medicines European public assessment report (EPAR): Mircera, methoxy polyethylene glycol-epoetin beta, Date of authorisation: 20/07/2007, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 15, 2025 0

Human medicines European public assessment report (EPAR): Mircera, methoxy polye...

EMA business hours over Easter holiday period

EMA business hours over Easter holiday period

Apr 15, 2025 0

EMA business hours over Easter holiday period

Policy 26: Records management and archives policy

Apr 15, 2025 0

Policy 26: Records management and archives policy

1
2
3
4

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.